https://www.yiliao.com/index.php?action=history&feed=atom&title=BEACON_%E6%96%B9%E6%A1%88
BEACON 方案 - 版本历史
2026-04-09T18:36:20Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=BEACON_%E6%96%B9%E6%A1%88&diff=316109&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-28T20:12:19Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>BEACON 方案</strong>（BEACON CRC Protocol）是指基于里程碑式 III 期临床试验（BEACON CRC）确立的，用于治疗既往接受过治疗的 <strong><i>BRAF</i> V600E</strong> 突变转移性结直肠癌（mCRC）的靶向联合治疗方案。该方案的核心策略是“<strong>双靶点抑制</strong>”：联合使用 <strong>Encorafenib</strong>（BRAF 抑制剂）和 <strong>Cetuximab</strong>（西妥昔单抗，EGFR 抑制剂），部分研究也包含 Binimetinib（MEK 抑制剂）作为三药方案。BEACON 方案的获批改变了该亚型肠癌的临床实践，使其成为首个不含细胞毒化疗药物的一线/二线标准治疗。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">BEACON 方案</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Targeted Therapy for BRAF mCRC (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">机制：阻断 EGFR 介导的反馈激活</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">方案概览</th><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">适应症</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><i>BRAF</i> V600E mCRC</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">核心药物 A</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;"><strong>Encorafenib</strong> (BRAFi)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">核心药物 B</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;"><strong>Cetuximab</strong> (EGFRi)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">临床地位</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">二线及以上标准治疗 (SOC)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569;">试验代号</th><br />
<td style="padding: 6px 12px; color: #64748b;">NCT02928224</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子逻辑：合成致死的完美演绎</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
BEACON 方案是“机制驱动临床”的典范，其设计初衷是为了解决单药 BRAF 抑制剂在结直肠癌中无效的难题：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>耐药困境：</strong> <br />
<br>在黑色素瘤中，单药抑制 BRAF V600E 效果显著；但在结直肠癌中，抑制 BRAF 会导致负反馈信号解除，迅速诱导上游 <strong>EGFR</strong> 的代偿性激活，从而重新激活 MAPK 通路。</li><br />
<li style="margin-bottom: 12px;"><strong>双重封锁 (Vertical Blockade)：</strong> <br />
<br>BEACON 方案同时引入 <strong>Cetuximab</strong> 封锁上游的 EGFR 受体，和 <strong>Encorafenib</strong> 封锁下游突变的 BRAF 蛋白。这种“上下夹击”的垂直抑制策略切断了肿瘤细胞的逃逸路径。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床数据：双药 vs 三药</h2><br />
<br />
<div style="background-color: #fff7ed; border-left: 5px solid #ea580c; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<p style="margin: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
<strong>关键结论：</strong> 虽然试验设计了三药组（加用 MEK 抑制剂 Binimetinib），但最终数据表明，<strong>双药方案（双靶）</strong>在生存获益上与三药方案相当，且毒性更低。因此，双药方案成为目前的优选推荐。<br />
</p><br />
</div><br />
<br />
<div style="overflow-x: auto; margin: 20px auto;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f1f5f9; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">分组</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; width: 25%;">中位 OS (月)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; width: 25%;">客观缓解率 (ORR)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">毒性特征</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">三药联合<br><span style="font-weight:normal; font-size:0.9em">(Enco + Cetux + Bini)</span></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">9.3</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">26.8%</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">腹泻、皮疹、贫血发生率较高。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; background-color: #eff6ff; color: #1e40af;">双药联合 (BEACON)<br><span style="font-weight:normal; font-size:0.9em">(Enco + Cetux)</span></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #eff6ff;"><strong>9.3</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #eff6ff;">20%</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #eff6ff;">耐受性良好，主要是 EGFR 相关的皮肤毒性。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">对照组<br><span style="font-weight:normal; font-size:0.9em">(伊立替康 + Cetux)</span></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">5.9</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">2%</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">典型的化疗毒性。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗地位与指南推荐</h2><br />
<br />
<div style="background-color: #f0f9ff; border-left: 5px solid #1e40af; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #1e40af; font-size: 1.1em;">NCCN 指南首选</h3><br />
<p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
基于 BEACON 研究结果，<strong>Encorafenib + Cetuximab</strong>（或 Panitumumab）已被 NCCN 指南列为 <i>BRAF</i> V600E 突变 mCRC 二线治疗的<strong>首选方案（Category 2A）</strong>。对于体能状态较差不适合一线强烈化疗（如 FOLFOXIRI + Bevacizumab）的患者，该方案也可作为一线治疗的替代选择。<br />
</p><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review]</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Kopetz S, et al. (2019).</strong> <em>Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.</em> <strong>[[New England Journal of Medicine]]</strong>. <br><br />
<span style="color: #475569;">[点评]：BEACON CRC 的主文献，确立了无化疗靶向方案在 BRAF 突变肠癌中的优越性。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Tabernero J, et al. (2021).</strong> <em>Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutated metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON CRC study.</em> <strong>[[Journal of Clinical Oncology]]</strong>. <br><br />
<span style="color: #475569;">[点评]：更新的数据分析，进一步证实了双药方案与三药方案疗效相当，从而确立了双药作为标准治疗。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
BEACON 方案 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">分子靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[BRAF]] V600E • [[EGFR]] • [[MAPK通路]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">相关药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Encorafenib]] • [[Cetuximab]] • [[Binimetinib]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">治疗策略</td><br />
<td style="padding: 10px 15px; color: #334155;">[[双重抑制]] • [[合成致死]] • [[去化疗]] (Chemo-free)</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020